Cytokinetics (CYTK) Reports Licensing Collaboration & Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. ABBV
8. USO
9. MSFT
10. IBM

Go back to Cytokinetics (CYTK) Reports Licensing Collaboration & Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor

Cytokinetics (CYTK) Announces Proposed $150M Share Common Offering

July 15, 2020 4:01 PM EDT

Cytokinetics, Incorporated (NASDAQ: CYTK) today announced plans to offer, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or... More

UPDATE: Raymond James Starts Cytokinetics (CYTK) at Strong Buy

July 10, 2020 3:30 AM EDT

(Updated - July 10, 2020 5:50 AM EDT)

(updating comment)

Raymond James analyst Dane Leone initiates coverage on Cytokinetics (NASDAQ: CYTK) with a Strong Buy rating and a price target of $39.00.

The analyst comments "Our thesis is based upon three key points: 1)... More